In his ppt one can get all the information about Britannia company swot , pest analysis ,logo , market share, advertising , history, sub products , sales promotion strategy
Successful entrepreneur (kiran muzumdar shaw) by saisai guntapelliwar
successful entrepreneurs- kiran muzumdar shaw . It is a ppt on the successful leader and the richest women in India and the worlds 7th largest pharmaceutical company chairman kiran muzumdar shaw .The story behind her success and journy how she face the problem and overcome from that situation.
This presentation help you to understand the structural evolution of the Biocon. How the organization structure as well as organization design changes in Biocon, it is fully described here.
In his ppt one can get all the information about Britannia company swot , pest analysis ,logo , market share, advertising , history, sub products , sales promotion strategy
Successful entrepreneur (kiran muzumdar shaw) by saisai guntapelliwar
successful entrepreneurs- kiran muzumdar shaw . It is a ppt on the successful leader and the richest women in India and the worlds 7th largest pharmaceutical company chairman kiran muzumdar shaw .The story behind her success and journy how she face the problem and overcome from that situation.
This presentation help you to understand the structural evolution of the Biocon. How the organization structure as well as organization design changes in Biocon, it is fully described here.
The Top 5 Trusted Nutri Ingredient Suppliers & Manufacturers of 2023.pdfinsightscare
In this edition of Insights Care, The Top 5 Trusted Nutri Ingredient Suppliers & Manufacturers of 2023, you will discover Nutri Ingredient Suppliers & Manufacturers
Biopharmaceuticals are an essential therapeutic option accounting for a substantial part of the global therapeutic market. With the patents of many blockbuster drugs coming to an end, an opportunity has arisen for the manufacture and approval of biosimilars. Visiongain\'s 9th Biosimilars Conference will look at the multiple facets of biosimilars, ranging from the evolving regulatory landscape and challenges in clinical development, to the legal and economic aspects.
Quality for Biologics ' New ReportCritical quality attributes, process and change control, product variation, characterisation, and regulatory concernsSales of biologics grew by 20% in 2007, far faster than sales of small molecule drugs, which grew by not much more than 5%. The number of biologics being launched is also growing very rapidly, accounting for more than 25% of launches in 2007. But biologics are not like small molecules ' they are more complex to develop, test and produce. Any change in production may have a direct effect on both safety and efficacy. Making sure that development, testing and production is done correctly can be expensive, but getting it wrong can be even more expensive and may be disastrous for patients and for the companies involved.This unique 300 page report can help you to understand the processes involved ' knowledge that can save time and money and even make the difference between success and failure. The report covers all aspects of the subject including' Critical quality attributes ' Manufacturing process parameters' Process analytical technology' Physicochemical analysis,' Bioassays, ' Formulation and specifications' Product- and process-related impurities' Aggregation ' Non-clinical testing' Clinical development, ' Post-marketing period' Regulatory authority expectations' Risk management ' Comparability concernsQuality for Biologics is edited by Dr Nicole Lyscom and is written by senior industry experts from leading companies and organisations including:UCBUCB-CelltechEli LillyAmgenRocheParexel ConsultingGenentech